Navigation Links
BioVex Agrees SPA With the FDA for a Pivotal Phase III Study With OncoVEX (GM-CSF) in Head and Neck Cancer
Date:9/15/2009

ession is responsible for the majority of deaths. The two year loco-regional failure rate following front line treatment is around 30% with a further 20% of patients progressing at a distant site. The long-term loco-regional control rate of 100% combined with the high percentage of patients that remain disease free at up to 40 months from treatment is very encouraging and provides confidence that OncoVEX (GM-CSF) will significantly reduce relapse rates as compared to standard therapy alone in the pivotal study recently agreed with the FDA."

About Head and Neck Cancer

Head and neck cancer accounts for 47,000 new cases (3% of all new cancer cases and 2% of all cancer deaths) in the United States annually; it is the fifth most common malignancy worldwide (an estimated 644,000 new cases annually).

Patients with locally advanced tumors are best treated with concurrent chemoradiation, with planned neck dissection indicated in certain patients. Despite aggressive treatment of locally advanced disease loco-regional recurrences develop in 30% of patients and distant metastases in 20%. Aggressive combined modality therapy may be frequently associated with debility, and numerous physical and psychological symptoms including pain, dysphagia, weight loss, disfigurement, depression, and xerostomia (dry mouth). As a result, new and improved, and less toxic therapies for head and neck cancer are urgently required.

About BioVex

BioVex is a privately held biotechnology company based in Woburn, MA where it also has an operational launch grade manufacturing facility. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

The Company's lead cancer technology platform, OncoVEX (GM-CSF) is a first-in-class oncolytic, or cancer destroying virus technology. OncoVEX (GM-CSF) designed to work by; repli
'/>"/>

SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma
2. BioVex Raises $40 Million in First Close of Series F Financing
3. BioVex to Present at the UBS Global Life Sciences Conference
4. BioVex Closes Second Round of Series E Financing
5. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
6. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
7. CardioDynamics Agrees to be Acquired by SonoSite for $1.35 Per Share
8. MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
9. PharmaNet Development Group Agrees to be Acquired by JLL Partners
10. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
11. Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... ... R-Biopharm is proud to announce the RIDASCREEN® Gliadin Competitive ... been accepted by AOAC International as Official First Action method. The AOAC Official ... R5 Competitive ELISA,” based on a specific monoclonal antibody to potentially celiac toxic ...
(Date:7/30/2015)... ... 30, 2015 , ... The 2015 Market Research Report on the Global ... the global Propanol market with a focus on the Chinese situation. Major companies included ... Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , ...
(Date:7/30/2015)...  With over 60,000 customers across the globe, ISN improves the efficiency and effectiveness ... more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In ... Headquartered in Dallas, TX , ISN has additional ...
(Date:7/30/2015)... Bedford, NH (PRWEB) , ... July 30, 2015 ... ... efficiency homogenizer for advanced fluid applications and designed for continuous operation up to ... clean-in-place and sterilization-in-place, ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... "personal genomics," featuring five of the most outstanding scientists, physicians and ... Bio-IT World Conference & Expo being held April 27-29 at the ... ... (PRWEB) March 31, 2009 -- A plenary panel discussion on the ...
... FREDERICK, Md., March 31 ImQuest Life Sciences ... development of the pyrimidinedione small molecules as antiviral ... Hepatitis and Liver Disease meeting held last week ... identified ten pyrimidinediones as inhibitors of HBV replication, ...
... Codexis, Inc. today announced Lori Giver, Ph.D., has ... Systems Biology for Codexis Bioindustrials. She is responsible ... Dr. Giver reports to David Anton, Ph.D., Vice President, ... researcher in the directed evolution of genes and proteins. ...
Cached Biology Technology:Keynote Panel at Bio-IT World Expo to Feature Five Leaders in the Field of "Personal Genomics" 2Keynote Panel at Bio-IT World Expo to Feature Five Leaders in the Field of "Personal Genomics" 3Keynote Panel at Bio-IT World Expo to Feature Five Leaders in the Field of "Personal Genomics" 4Keynote Panel at Bio-IT World Expo to Feature Five Leaders in the Field of "Personal Genomics" 5ImQuest Presents Data on the Anti-Hepatitis B Virus Activity of Pyrimidinediones at the 13th ISVHLD Meeting in Washington D.C. 2Codexis Names Lori Giver VP Systems Biology 2
(Date:7/27/2015)... LOS ANGELES , July 27, 2015 /PRNewswire/ ... providing evidence- and experience-based clinical improvement solutions, today ... coordination solution is now available on Android smartphones ... at inpatient and post-care organizations can use ZynxCarebook ... the same patient,s condition, streamline care transitions to ...
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. ... a biometric authentication company focused on the growing ... smart wallet, announces that it has filed provisional ... and Method. This invention highlights ... only authorizes an account, but also the user ...
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION ... new convenient and secure method to make payments.  ... payment methods, introduced with its groundbreaking voice-direct payment ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... report on a new way of preventing potentially harmful plasticizers ... migrating from one of the most widely used groups of ... polyvinyl chloride (PVC) plastics that are safer than those now ... say. Their study is in ACS, Macromolecules , a ...
... 2, 2010 -- A hormone responsible for the body,s stress ... in the pancreas, according to JDRF- funded researchers at the ... are the latest advances to underscore the potential for regeneration ... 1 diabetes. The research, which was published ...
... North Carolina State University have developed a "smart coating" that ... off infection. When patients have hip, knee or dental ... reject the implant. But the smart coating developed at NC ... implant. The coating creates a crystalline layer next to the ...
Cached Biology News:JDRF-funded research advances potential for regeneration as a possible cure for type 1 diabetes 2Smart coating opens door to safer hip, knee and dental implants 2
Practical tool for easy, effective sealing of 0.2ml PCR tubes and plates using cap strips....
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... Time- and temperature-controlled microwave ... Rehydration and Antigen Retrieval of ... offers ease of use, high ... and high performance. When used ...
... discovery system miniaturizes, integrates and automates ... LabChip technology, the LabChip 3000 performs ... flow fashion. LabChip assays are separations-based, ... what is achievable in homogenous, well-based ...
Biology Products: